Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2937

Sort by

Sort Order Select

Journal Articles

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Mounica Vallurupalli, Nancy Berliner

Blood (2019) 134 (21): 1783–1786.

https://doi.org/10.1182/blood.2019002289

Published: 2019

Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD

Blood (2019) 134 (Supplement_1): 2333.

https://doi.org/10.1182/blood-2019-123995

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD

Blood (2019) 134 (Supplement_1): 4767.

https://doi.org/10.1182/blood-2019-123688

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 926.

https://doi.org/10.1182/blood-2019-125871

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Rui Lv, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 784.

https://doi.org/10.1182/blood-2019-127659

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Zinaida Good, PhD, Jay Y. Spiegel, MDFRCPC, Bita Sahaf, PhD, Meena B. Malipatlolla, Matthew J. Frank, MD PhD, John Baird, MD, Lori S Muffly, MD, Gursharan K. Claire, MPH, Juliana Craig, BA, Katherine A. Kong, Sean Bendall, PhD, David B Miklos, MD PhD, Crystal L. Mackall, MD

Blood (2019) 134 (Supplement_1): 779.

https://doi.org/10.1182/blood-2019-130815

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only